Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment : Episode 11
Opinion
Video
PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies
Author(s):
Key Takeaways
- Olaparib significantly improved radiographic progression-free survival and overall survival in metastatic prostate cancer with HRR gene alterations.
- Safety profiles of PARP inhibitors were consistent with known effects, with manageable adverse events observed.
Panelists discuss how the PROfound trial (NCT02987543) demonstrated the efficacy and safety of olaparib monotherapy in metastatic prostate cancer patients with homologous recombination repair gene alterations, highlighting its potential as a targeted treatment option and its impact on the landscape of precision medicine in prostate cancer management.
Video Player is loading.
Video Content above is prompted by the following:
- Discuss efficacy and safety findings from monotherapy trials PARP inhibitors in metastatic prostate cancer harboring homologous recombination repair gene alterations.
- PROfound trial (olaparib), NCT02987543
Related Videos
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Checkpoint Inhibitors for Treatment of NMIBC
Communication of Treatment Options for High-Risk NMIBC
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
BPH: The Patient Journey
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
Addressing Remaining Unmet Needs in mCRPC
Use and Sequencing of Novel Treatments in NMIBC
Related Content
